OncoMatch

OncoMatch/Clinical Trials/NCT06389123

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

Is NCT06389123 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. for metastatic cancer.

Phase 1RecruitingUniversity of California, DavisNCT06389123Data as of May 2026

Treatment: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. — This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: systemic therapy — metastatic

documented tumor progression for metastatic disease during or following at least one prior FDA approved systemic regimen (Androgen Deprivation allowed)

Cannot have received: external beam radiation therapy

External beam radiation therapy (EBRT) or radiopharmaceutical treatment within 21 days prior to study day 1

Cannot have received: radiopharmaceutical treatment

External beam radiation therapy (EBRT) or radiopharmaceutical treatment within 21 days prior to study day 1

Lab requirements

Blood counts

Absolute neutrophil count (ANC) ≥ 1000 cells/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin ≥ 8 g/dL

Kidney function

Creatinine ≤ 2 times ULN

Liver function

AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN); Total bilirubin ≤ 2 times ULN

Cardiac function

No Class 3 or 4 NYHA Congestive Heart Failure

Hematologic parameters defined as: ANC ≥ 1000 cells/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 8 g/dL; Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5x ULN; Total bilirubin ≤ 2x ULN; Creatinine ≤ 2x ULN; Participants with Class 3 or 4 NYHA Congestive Heart Failure [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • The University of California Davis Comprehensive Cancer Center · Sacramento, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify